{"id":"W4220744079","doi":"10.1016/j.annonc.2022.03.008","title":"VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; European Society for Medical Oncology; Cancer Council Victoria; Eisai; Department of Health, State Government of Victoria; National Breast Cancer Foundation; National Health and Medical Research Council; Cancer Research UK; Invitae; Gilead Sciences; Merck KGaA; Eli Lilly and Company; American Association for Cancer Research; AstraZeneca; Myriad Genetics; National Cancer Research Institute; Teva Pharmaceutical Industries; Pfizer; Daiichi Sankyo Europe; Breast Cancer Research Foundation; U.S. Department of Health and Human Services","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Oncology; Placebo; Breast cancer; Cancer; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004096996,0.001218222,0.001270471,0.000262537,0.0001501987,0.001233055,0.000904588,0.0007269338,0.002749972],"category_scores_gemma":[0.00205531,0.0003314723,0.002151602,0.0002579299,0.000580654,0.0006355997,0.0005308669,0.002234747,0.000363695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007858407,"about_ca_system_score_gemma":0.0008901788,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004085419,"about_ca_topic_score_gemma":0.001416376,"domain_scores_codex":[0.9991335,0.0005722878,0.00002155562,0.0001374541,0.000047964,0.00008724524],"domain_scores_gemma":[0.9991291,0.0003868074,0.0001582512,0.00009716016,0.00003114664,0.000197392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8122967,0.006360239,0.03486263,0.0008315719,0.006393542,0.0001883044,0.0001418289,0.02034241,0.01790464,0.001273295,0.005653319,0.09375147],"study_design_scores_gemma":[0.3686469,0.3363134,0.1576152,0.0002646601,0.01178781,0.001262077,0.000281402,0.08645164,0.01585846,0.006052952,0.01518997,0.0002755154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942194,0.001199114,0.0008502305,0.0003810963,0.00007433034,0.0002483187,0.001751729,0.00008595262,0.001189837],"genre_scores_gemma":[0.9917021,0.000451657,0.001491253,0.0003815143,0.0001029874,0.0004498749,0.003792678,0.00004847008,0.001579374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004096996,"threshold_uncertainty_score":0.02166724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07982892465250224,"score_gpt":0.4337723077020927,"score_spread":0.3539433830495904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}